Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes
The main benefits of GLP-1 therapy include: Enhanced insulin secretion in response to meals Reduced glucagon release, preventing high blood sugar levels Slowed gastric emptying, leading to prolonged satiety Decreased appetite, which may help with weight loss Currently available GLP-1 receptor agonists include drugs like liraglutide (Victoza), semaglutide (Ozempic, Wegovy), exenatide (Byetta), and dulaglutide (Trulicity)
It increases thermogenesis
#Diabetes #DiabetesCare #GlycemicControl #ChronicDiseaseManagement #Endocrinology #PatientCare #MedicalEducation #ClinicalPractice #Healthcare #DoctorsOfLinkedIn #PreventiveMedicine To view or add a comment, sign in This study supports the safe use of metformin in transplant recipients living with diabetes, demonstrating an association with improved survival and cardiovascular outcomes and graft preservation
754-P: effect of retatrutide on kidney parameters in people with type 2 diabetes and/or obesity a post-hoc analysis of two phase 2 trials
